Cart (0 Items)
Your cart is currently empty.
View ProductsMogamulizumab Biosimilar – Anti-CCR4, CD194 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Mogamulizumab Biosimilar - Anti-CCR4, CD194 mAb - Research Grade |
|---|---|
| Source | CAS 1159266-37-1 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Mogamulizumab,AMG-761,KW-0761,CCR4, CD194,anti-CCR4, CD194 |
| Reference | PX-TA1258 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
Description of Mogamulizumab Biosimilar - Anti-CCR4/CD194 mAb - Research Grade
General information on Anti-CCR4/CD194[Homo sapiens] (Mogamulizumab) Monoclonal Antibody
Mogamulizumab targets CC chemokine receptor 4 (CCR4) and is used for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS) which are subtypes of cutaneous T-cell lymphoma.
Related products
SIL
Reviews
Il n’y a pas encore d’avis.